user
menu
letter
Sign InRegister
langEnglisharrow

DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (MALS verified)

Cat. No. / Size
Price
Availability
Qty
ENN-D5244-50ug
$465.00
In Stock - Delivery in 1-2 business days
ENN-D5244-500ug
$2,885.00
In Stock - Delivery in 1-2 business days
ENN-D5244
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

Envelope Protein/E Protein (DENV)

Source

DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (ENN-D5244) is expressed from human 293 cells (HEK293). It contains AA Met 281 - Ser 677 (Accession # P29990).

Molecular Characterization

This protein carries a polyhistidine tag at the N-terminus.

The protein has a calculated MW of 46.2 kDa. The protein migrates as 55-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

The protein is designed as a dimer.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, 0.5 M Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System

Background

Dengue is a mosquito-borne viral disease widely spread all over the world transmitted by 4 serotypes of dengue virus (DENV). The symptoms range from mild dengue fever to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with high mortality. Currently, most of the studies on DENV vaccines emphasize on its envelope protein which is essential for viral attachment and fusion (i.e., Sanofi’s tetravalent dengue vaccine Dengvaxia). However, the vaccine of envelope protein still needs to be improved to maximize its efficiency on people never infected with DENV before, which requires more research to be conducted on the DENV envelope protein.